Drug Type Small molecule drug |
Synonyms Tegobuvir (USAN/INN), GS-333126, GS-9190 |
Target |
Action inhibitors |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H14F7N5 |
InChIKeyXBEQSQDCBSKCHJ-UHFFFAOYSA-N |
CAS Registry1000787-75-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Oct 2008 | |
Chronic hepatitis C genotype 1 | Phase 2 | Belgium | 01 Oct 2008 | |
Chronic hepatitis C genotype 1 | Phase 2 | Germany | 01 Oct 2008 | |
Chronic hepatitis C genotype 1 | Phase 2 | Ireland | 01 Oct 2008 | |
Chronic hepatitis C genotype 1 | Phase 2 | Poland | 01 Oct 2008 | |
Chronic hepatitis C genotype 1 | Phase 2 | Puerto Rico | 01 Oct 2008 | |
Chronic hepatitis C genotype 1 | Phase 2 | United Kingdom | 01 Oct 2008 |